Breaking News Instant updates and real-time market news.

TEVA

Teva

$46.30

0.29 (0.63%)

, AGN

Allergan

$229.76

-0.55 (-0.24%)

09:58
10/03/16
10/03
09:58
10/03/16
09:58

Teva completes acquisition of Anda from Allergan

Teva Pharmaceutical (TEVA) announced that it has completed its acquisition of Anda, Inc., a distributor of generic pharmaceuticals in the U.S., from Allergan (AGN). Teva currently has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. "We are pleased that Anda, Inc., one of the leading distributors of generic medicines in the U.S., is now part of Teva. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for our business and for our extensive supply chain network in particular," said Siggi Olafsson, President & CEO of Global Generic Medicines. "This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

TEVA

Teva

$46.30

0.29 (0.63%)

AGN

Allergan

$229.76

-0.55 (-0.24%)

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$46.30

0.29 (0.63%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
AGN Allergan
$229.76

-0.55 (-0.24%)

09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.

TODAY'S FREE FLY STORIES

WAB

Wabtec

$84.38

2.19 (2.66%)

20:53
04/25/17
04/25
20:53
04/25/17
20:53
Upgrade
Wabtec rating change at KeyBanc »

Wabtec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 10

    May

CONN

Conn's

$14.80

0.3 (2.07%)

20:53
04/25/17
04/25
20:53
04/25/17
20:53
Upgrade
Conn's rating change at KeyBanc »

Conn's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SITE

SiteOne Landscape

$48.20

-0.4 (-0.82%)

20:43
04/25/17
04/25
20:43
04/25/17
20:43
Syndicate
SiteOne Landscape 10M share Secondary priced at $47.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 26

    Apr

20:24
04/25/17
04/25
20:24
04/25/17
20:24
Periodicals
Trump tax plan to propose 10% tax on offshore profits, Bloomberg says »

President Donald Trump…

20:17
04/25/17
04/25
20:17
04/25/17
20:17
Periodicals
Trump administration drops support for border adjustment tax, NYT says »

The Trump administration…

DIS

Disney

$115.18

1.48 (1.30%)

20:11
04/25/17
04/25
20:11
04/25/17
20:11
Periodicals
ESPN layoffs could be harsher than expected, Sporting News says »

Layoffs at Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$110.82

2.81 (2.60%)

, AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

20:09
04/25/17
04/25
20:09
04/25/17
20:09
Periodicals
AkzoNobel says analysis of PPG offer to take time, Bloomberg reports »

AkzoNobel (AKZOY)…

PPG

PPG

$110.82

2.81 (2.60%)

AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

, TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

20:04
04/25/17
04/25
20:04
04/25/17
20:04
Hot Stocks
FCC chairman vows review of media ownership rules »

In a speech to the…

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

CBS

CBS

$66.41

0.46 (0.70%)

NXST

Nexstar

$68.90

0.3 (0.44%)

CMCSA

Comcast

$38.49

0.48 (1.26%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 09

    May

  • 22

    May

  • 23

    May

  • 15

    Jun

FB

Facebook

$146.49

1.02 (0.70%)

19:57
04/25/17
04/25
19:57
04/25/17
19:57
Periodicals
Facebook tests news discovery methods, The Information says »

Facebook is testing new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AVGO

Broadcom

$223.20

1.96 (0.89%)

, BRCD

Brocade

$12.58

0.01 (0.08%)

19:54
04/25/17
04/25
19:54
04/25/17
19:54
Periodicals
Broadcom, Brocade offer behavioral remedies to EU regulators, CTFN says »

Broadcom (AVGO) has…

AVGO

Broadcom

$223.20

1.96 (0.89%)

BRCD

Brocade

$12.58

0.01 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$146.49

1.02 (0.70%)

19:52
04/25/17
04/25
19:52
04/25/17
19:52
Hot Stocks
Facebook tests expanded 'Related Articles' feature »

Facebook announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

19:47
04/25/17
04/25
19:47
04/25/17
19:47
Periodicals
Trump administration considers additional trade actions, WSJ says »

The Trump administration…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

, PEP

PepsiCo

$114.16

-0.16 (-0.14%)

19:25
04/25/17
04/25
19:25
04/25/17
19:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

PEP

PepsiCo

$114.16

-0.16 (-0.14%)

BA

Boeing

$183.51

1.45 (0.80%)

UTX

United Technologies

$116.87

0.55 (0.47%)

TMO

Thermo Fisher

$158.81

1.47 (0.93%)

GD

General Dynamics

$193.24

1.33 (0.69%)

ANTM

Anthem

$172.46

4.05 (2.40%)

NOC

Northrop Grumman

$248.13

-1.01 (-0.41%)

WM

Waste Management

$74.23

0.13 (0.18%)

IR

Ingersoll-Rand

$85.66

1.47 (1.75%)

DPS

Dr Pepper Snapple

$98.41

0.16 (0.16%)

HES

Hess Corp.

$48.64

0.98 (2.06%)

WYN

Wyndham

$92.22

0.43 (0.47%)

FLIR

FLIR Systems

$37.51

0.27 (0.73%)

NDAQ

Nasdaq

$70.53

0.08 (0.11%)

STT

State Street

$80.62

0.83 (1.04%)

APH

Amphenol

$72.18

0.25 (0.35%)

ROK

Rockwell Automation

$160.14

3.19 (2.03%)

BAX

Baxter

$53.21

-0.24 (-0.45%)

NSC

Norfolk Southern

$116.78

-0.27 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 06

    May

  • 11

    May

  • 17

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 15

    Jun

VZ

Verizon

$46.70

-0.35 (-0.74%)

19:20
04/25/17
04/25
19:20
04/25/17
19:20
Hot Stocks
Verizon introduces unlimited prepaid plan »

Verizon announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

NTB

Butterfield

$32.19

0.07 (0.22%)

19:12
04/25/17
04/25
19:12
04/25/17
19:12
Earnings
Butterfield reports Q1 core EPS 70c, consensus 64c »

Reports Q1 revenue $107M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NBIX

Neurocrine

$53.62

1.84 (3.55%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
Neurocrine prices 30-count bottle of Ingrezza at $5,275 »

Neurocrine disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

MNOV

MediciNova

$5.57

0.14 (2.58%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
MediciNova: Survival rate from MN-166 open-label period 'significantly higher' »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOX

21st Century Fox

$29.89

0.14 (0.47%)

, FOXA

21st Century Fox

$30.61

0.26 (0.86%)

18:50
04/25/17
04/25
18:50
04/25/17
18:50
Periodicals
8 more employees join Fox News lawsuit over race discrimination, FT says »

Eight current and former…

FOX

21st Century Fox

$29.89

0.14 (0.47%)

FOXA

21st Century Fox

$30.61

0.26 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

, CG

Carlyle Group

$16.70

0.05 (0.30%)

18:44
04/25/17
04/25
18:44
04/25/17
18:44
Periodicals
Albany Molecular receives interest from Pamplona, Carlyle, Bloomberg says »

Albany Molecular (AMRI)…

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

CG

Carlyle Group

$16.70

0.05 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 06

    Jun

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.